🇺🇸 Aquestive Therapeutics, Inc.
Forum topic · AQST · Company page: financials, ownership and filings
Join the discussion on Aquestive Therapeutics, Inc.
Loading…
Results announced on 3 November 2026
Aquestive Therapeutics, Inc. announced results on 3 November 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $8 million (down 41% from a year earlier) and a net loss of $16 million.
Insider trading in October 2026
Directors and officers of Aquestive Therapeutics, Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 1 insider sold shares worth about $105,600 in 1 trade.
Awards, option exercises and shares withheld for tax are not counted.
Mutual funds: 95 funds hold $80 million
95 mutual funds in 1 country hold shares of Aquestive Therapeutics, Inc. worth $80 million, about 15.8% of the company (funds' newest reports, up to 31 July 2026).
Since their previous reports 60 funds added shares and 26 sold; on balance they bought $11 million. Share splits are not counted as trading.
Source: Automatic updates: SEC filings, regulators' notices and fund reports held on this site. Posts marked 🤖 are written automatically from official data and state no opinion. Member comments are their authors' views, shown after an editor's review; they are not investment advice.